Short interruptions of TNF-inhibitor treatment can be associated with treatment failure in patients with immune-mediated diseases.

Tea LambergTaina SipponenSanna ValtanenKari K EklundTarja MälkönenKristiina Aalto Katriina MikolaKaija-Leena KolhoSanna LeinonenPia IsomäkiHeidi MäkinenKrista-Liisa VidqvistArto KokkoLaura HuilajaMinna KyllönenPaula KeskitaloSirja SardPaula VähäsaloRitva KoskelaLiisa KrögerPerttu LahtinenAnna-Maija HaapalaKatja KorkattiTuulikki Sokka-IslerT Sakari Jokirantanull null

Published in: Autoimmunity (2022)

Our results suggest that the interruptions of the treatment with TNF-inhibitors expose patients to immunisation and increase the need for drug switching. These findings stress the importance of careful judgement of the need for a short interruption in the biological treatment in clinical work, especially during non-severe infections.

Keyphrases

rheumatoid arthritis
end stage renal disease
emergency department
chronic kidney disease
early onset
prognostic factors
drug induced